Pub Date : 2025-01-01DOI: 10.1016/j.remn.2024.500028
L. Bian , C. Yang , S.-w. Yin , C.-f. Ni
{"title":"Efecto antitumoral de la vertebroplastia en la metástasis vertebral basado en el análisis cuantitativo de la PET/TC con 18F-FDG","authors":"L. Bian , C. Yang , S.-w. Yin , C.-f. Ni","doi":"10.1016/j.remn.2024.500028","DOIUrl":"10.1016/j.remn.2024.500028","url":null,"abstract":"","PeriodicalId":48986,"journal":{"name":"Revista Espanola De Medicina Nuclear E Imagen Molecular","volume":"44 1","pages":"Article 500028"},"PeriodicalIF":1.6,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143095661","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-01-01DOI: 10.1016/j.remn.2024.500067
D. Tercero Garrido , M.V. Guiote Moreno , C. Rodelo-Haad , P.I. Contreras Puertas , S. Soriano Cabrera , M.D. Albalá González
Objective
To assess the usefulness of peritoneal cavity scintigraphy and the contribution of SPECT/CT in patients on peritoneal dialysis with suspected leak.
Methodology
An observational case series study is carried out. It consists of a longitudinal, retrospective and descriptive study. 11 patients on peritoneal dialysis were studied and it was realiced a peritoneal cavity scintigraphy test and SPECT/CT to evaluate a peritoneal leak.
Results
In 54,5% of the patients, a positive study of peritoneal leak was obtained. The most frequent localitations were in the abdominal wall at the catheter entry level and the inguinal hernia. In the cases with sintomatology like pain and celullitis of the subcutaneous tract of the cateter the frequent of leak was 100%. There was a change in therapeutic management in patients with a positive study. There was not relevant changes in initial dialysis regimen in patients with a negative study. In this cases, except for one patient who required hemodialysis, all patients experienced clinical improvement.
Conclusions
Peritoneal scintigraphy and SPECT/CT study are non-invasive techniques that allow an adequate diagnosis and subsequent management of peritoneal leak.
{"title":"Gammagrafía peritoneal y SPECT/CT en el diagnóstico de fugas en pacientes en diálisis peritoneal","authors":"D. Tercero Garrido , M.V. Guiote Moreno , C. Rodelo-Haad , P.I. Contreras Puertas , S. Soriano Cabrera , M.D. Albalá González","doi":"10.1016/j.remn.2024.500067","DOIUrl":"10.1016/j.remn.2024.500067","url":null,"abstract":"<div><h3>Objective</h3><div>To assess the usefulness of peritoneal cavity scintigraphy and the contribution of SPECT/CT in patients on peritoneal dialysis with suspected leak.</div></div><div><h3>Methodology</h3><div>An observational case series study is carried out. It consists of a longitudinal, retrospective and descriptive study. 11 patients on peritoneal dialysis were studied and it was realiced a peritoneal cavity scintigraphy test and SPECT/CT to evaluate a peritoneal leak.</div></div><div><h3>Results</h3><div>In 54,5% of the patients, a positive study of peritoneal leak was obtained. The most frequent localitations were in the abdominal wall at the catheter entry level and the inguinal hernia. In the cases with sintomatology like pain and celullitis of the subcutaneous tract of the cateter the frequent of leak was 100%. There was a change in therapeutic management in patients with a positive study. There was not relevant changes in initial dialysis regimen in patients with a negative study. In this cases, except for one patient who required hemodialysis, all patients experienced clinical improvement.</div></div><div><h3>Conclusions</h3><div>Peritoneal scintigraphy and SPECT/CT study are non-invasive techniques that allow an adequate diagnosis and subsequent management of peritoneal leak.</div></div>","PeriodicalId":48986,"journal":{"name":"Revista Espanola De Medicina Nuclear E Imagen Molecular","volume":"44 1","pages":"Article 500067"},"PeriodicalIF":1.6,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143135593","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-01-01DOI: 10.1016/j.remn.2024.500073
E. Noriega-Álvarez , B. Rodríguez Alfonso , J.J. Rosales Castillo , A. Moreno Ballesteros , E. López Rodríguez , S. Sanz Viedma , M. del P. Orduña Diez , L. Domínguez Gadea
18F-FDG PET/CT has been positioned over time as a useful tool in the evaluation of osteoarticular infections, overcoming conventional explorations like MRI or bone scintigraphy in some indications. Its ability to provide functional and anatomical images simultaneously and its excellent resolution contributes to a more precise and personalised approach in the treatment of osteoarticular diseases such as spondylodiscitis. In addition, it has proven valuable in patients with suspected infection that is complex to diagnose or treat, improving detection in subclinical stages. However, some limitations have been identified, such as difficulty in the differential diagnosis of infection vs. inflammation (as in diabetic foot) or in the interpretation of patients with osteosynthesis materials. In this manuscript, we present a brief review providing general and practical information about the role of 18F-FDG PET/CT in infectious osteoarticular pathology, while part 2 discusses the role of 18F-FDG PET/CT in osteoarticular inflammation.
{"title":"Papel y aplicaciones de la 18F-FDG PET/TC en la evaluación de la infección e inflamación osteoarticular - Parte I","authors":"E. Noriega-Álvarez , B. Rodríguez Alfonso , J.J. Rosales Castillo , A. Moreno Ballesteros , E. López Rodríguez , S. Sanz Viedma , M. del P. Orduña Diez , L. Domínguez Gadea","doi":"10.1016/j.remn.2024.500073","DOIUrl":"10.1016/j.remn.2024.500073","url":null,"abstract":"<div><div><sup>18</sup>F-FDG PET/CT has been positioned over time as a useful tool in the evaluation of osteoarticular infections, overcoming conventional explorations like MRI or bone scintigraphy in some indications. Its ability to provide functional and anatomical images simultaneously and its excellent resolution contributes to a more precise and personalised approach in the treatment of osteoarticular diseases such as spondylodiscitis. In addition, it has proven valuable in patients with suspected infection that is complex to diagnose or treat, improving detection in subclinical stages. However, some limitations have been identified, such as difficulty in the differential diagnosis of infection vs. inflammation (as in diabetic foot) or in the interpretation of patients with osteosynthesis materials. In this manuscript, we present a brief review providing general and practical information about the role of <sup>18</sup>F-FDG PET/CT in infectious osteoarticular pathology, while part 2 discusses the role of <sup>18</sup>F-FDG PET/CT in osteoarticular inflammation.</div></div>","PeriodicalId":48986,"journal":{"name":"Revista Espanola De Medicina Nuclear E Imagen Molecular","volume":"44 1","pages":"Article 500073"},"PeriodicalIF":1.6,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143096746","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-01-01DOI: 10.1016/j.remn.2024.500064
I. Tobalina Larrea , J. Cuetos Fernández , A. Mendizabal Abad , A. Montero de la Peña , D. García Hernández , G.H. Portilla Quatrociocchi , M. Jiménez Alonso , M.C. Menchaca Echevarria
Objective
Describe our experience in treatment with Phosphorus-32 (32P) for refractory Philadelphia negative chronic myeloproliferative syndromes or with side effects to the usual treatment, its complications and risk of leukemic transformation.
Material and methods
Retrospective descriptive study including 17 patients with a diagnosis of Philadelphia-negative chronic myeloproliferative syndrome treated with 32P in our hospital from January 1985 to March 2017. Indications, response to treatment, as well as early and late complications have been analyzed.
Results
Of the 17 patients treated with 32P (11 men, 6 women; mean age 79.8 years), 6 patients had polycythemia vera and 11 essential thrombocytosis. A single dose was administered in 9 of the subjects, the rest required 2 or more doses due to inadequate hematological response and/or relapse. The total dose range of 32P administered was 116-951 MBq (median: 236 MBq). In 14 patients treated with 32P, complete or partial response was achieved in hematimetry. In 11 patients, the response was complete, established as a platelet count < 400.000/mm3 in those diagnosed with essential thrombocythemia and a hematocrit < 45% in cases of polycythemia vera. The median follow-up of patients from the date of the first treatment of 32P until study completion or death was 37 months (range: 5-230 months). Regarding early complications, 2 cases of anemia requiring blood transfusion were observed, and one case of mild thrombocytopenia. No leukemic transformation was identified.
Conclusions
In our experience, treatment with 32P has been a useful therapeutic option in Philadelphia-negative chronic myeloproliferative syndromes in elderly patients who showed poor tolerance and/or resistance to first-line treatment. No leukemic transformation was identified.
{"title":"Respuesta, complicaciones y riesgo de transformación leucémica del tratamiento con fósforo-32 en los síndromes mieloproliferativos crónicos Philadelphia negativos","authors":"I. Tobalina Larrea , J. Cuetos Fernández , A. Mendizabal Abad , A. Montero de la Peña , D. García Hernández , G.H. Portilla Quatrociocchi , M. Jiménez Alonso , M.C. Menchaca Echevarria","doi":"10.1016/j.remn.2024.500064","DOIUrl":"10.1016/j.remn.2024.500064","url":null,"abstract":"<div><h3>Objective</h3><div>Describe our experience in treatment with Phosphorus-32 (<sup>32</sup>P) for refractory Philadelphia negative chronic myeloproliferative syndromes or with side effects to the usual treatment, its complications and risk of leukemic transformation.</div></div><div><h3>Material and methods</h3><div>Retrospective descriptive study including 17 patients with a diagnosis of Philadelphia-negative chronic myeloproliferative syndrome treated with <sup>32</sup>P in our hospital from January 1985 to March 2017. Indications, response to treatment, as well as early and late complications have been analyzed.</div></div><div><h3>Results</h3><div>Of the 17 patients treated with <sup>32</sup>P (11 men, 6 women; mean age 79.8 years), 6 patients had polycythemia vera and 11 essential thrombocytosis. A single dose was administered in 9 of the subjects, the rest required 2 or more doses due to inadequate hematological response and/or relapse. The total dose range of <sup>32</sup>P administered was 116-951<!--> <!-->MBq (median: 236<!--> <!-->MBq). In 14 patients treated with <sup>32</sup>P, complete or partial response was achieved in hematimetry. In 11 patients, the response was complete, established as a platelet count<!--> <!--><<!--> <!-->400.000/mm<sup>3</sup> in those diagnosed with essential thrombocythemia and a hematocrit<!--> <!--><<!--> <!-->45% in cases of polycythemia vera. The median follow-up of patients from the date of the first treatment of <sup>32</sup>P until study completion or death was 37 months (range: 5-230 months). Regarding early complications, 2 cases of anemia requiring blood transfusion were observed, and one case of mild thrombocytopenia. No leukemic transformation was identified.</div></div><div><h3>Conclusions</h3><div>In our experience, treatment with <sup>32</sup>P has been a useful therapeutic option in Philadelphia-negative chronic myeloproliferative syndromes in elderly patients who showed poor tolerance and/or resistance to first-line treatment. No leukemic transformation was identified.</div></div>","PeriodicalId":48986,"journal":{"name":"Revista Espanola De Medicina Nuclear E Imagen Molecular","volume":"44 1","pages":"Article 500064"},"PeriodicalIF":1.6,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143105221","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-11-01DOI: 10.1016/j.remn.2024.500055
B. Karaşah Erkek , H. Sarıyıldız Gümüşgöz , A. Oral , B. Yazıcı , A. Akgün
Objective
Ablation therapy is employed in low-risk differentiated thyroid cancer (DTC) cases to facilitate patient monitoring by reducing thyroglobulin (Tg) levels to measurable levels below after surgery by eliminating residual thyroid tissue. However, there is still uncertainty about the minimum activity dose required for effective ablation. Opting for low-dose [131I]NaI for ablation offers several advantages for both patients and healthcare services. Particularly in this tumor group with a high life expectancy (approximately 90-95% at 10 years) [131I]NaI treatment should not pose a risk to the patient's post-treatment life and should not compromise their quality of life. However, there is a need for a well-defined identification of factors predicting successful ablation.
Methods
Clinical data, laboratory findings, and imaging tests of 287 patients with low-dose 1110 MBq (30 mCi) [131I]NaI ablation therapy for DTC were retrospectively reviewed. Post-ablation imaging and laboratory findings categorized ablation success/failure. The successful ablation group was determined according to the excellent response criteria outlined in ATA criteria. Relationships between clinical, pathological findings, biochemical common variables, and treatment failure were analyzed.
Results
An excellent response was achieved in 77% of the entire group according to ATA criteria post-ablation. Male gender and high Tg levels on the day of ablation (Tg cut-off: 10 ng/ml and 5.35 ng/ml) were associated with unsuccessful ablation.
Conclusions
Our results indicate that a 1110 MBq (30 mCi) ablation dose is sufficient to achieve an excellent response in most low-risk DTC cases 6-12 onths later. When selecting the dose for ablation, besides the histological markers mentioned in guidelines and age, we observed that stimulated Tg values and gender may be important in predicting ablation success.
{"title":"Terapia de ablación con yodo radiactivo de baja dosis (1,11 GBq) para el cáncer de tiroides diferenciado en el oeste de Turquía","authors":"B. Karaşah Erkek , H. Sarıyıldız Gümüşgöz , A. Oral , B. Yazıcı , A. Akgün","doi":"10.1016/j.remn.2024.500055","DOIUrl":"10.1016/j.remn.2024.500055","url":null,"abstract":"<div><h3>Objective</h3><div>Ablation therapy is employed in low-risk differentiated thyroid cancer (DTC) cases to facilitate patient monitoring by reducing thyroglobulin (Tg) levels to measurable levels below after surgery by eliminating residual thyroid tissue. However, there is still uncertainty about the minimum activity dose required for effective ablation. Opting for low-dose [<sup>131</sup>I]NaI for ablation offers several advantages for both patients and healthcare services. Particularly in this tumor group with a high life expectancy (approximately 90-95% at 10<!--> <!-->years) [<sup>131</sup>I]NaI treatment should not pose a risk to the patient's post-treatment life and should not compromise their quality of life. However, there is a need for a well-defined identification of factors predicting successful ablation.</div></div><div><h3>Methods</h3><div>Clinical data, laboratory findings, and imaging tests of 287 patients with low-dose 1110<!--> <!-->MBq (30<!--> <!-->mCi) [<sup>131</sup>I]NaI ablation therapy for DTC were retrospectively reviewed. Post-ablation imaging and laboratory findings categorized ablation success/failure. The successful ablation group was determined according to the excellent response criteria outlined in ATA criteria. Relationships between clinical, pathological findings, biochemical common variables, and treatment failure were analyzed.</div></div><div><h3>Results</h3><div>An excellent response was achieved in 77% of the entire group according to ATA criteria post-ablation. Male gender and high Tg levels on the day of ablation (Tg cut-off: 10<!--> <!-->ng/ml and 5.35<!--> <!-->ng/ml) were associated with unsuccessful ablation.</div></div><div><h3>Conclusions</h3><div>Our results indicate that a 1110 MBq (30<!--> <!-->mCi) ablation dose is sufficient to achieve an excellent response in most low-risk DTC cases 6-12<!--> <!--> onths later. When selecting the dose for ablation, besides the histological markers mentioned in guidelines and age, we observed that stimulated Tg values and gender may be important in predicting ablation success.</div></div>","PeriodicalId":48986,"journal":{"name":"Revista Espanola De Medicina Nuclear E Imagen Molecular","volume":"43 6","pages":"Article 500055"},"PeriodicalIF":1.6,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142658156","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-11-01DOI: 10.1016/j.remn.2024.500046
H. Önner, M.N. Calderon Tobar, L. Perktaş, F. Yilmaz, G. Kara Gedik
This study investigates the relationship between 18F-fluorodeoxyglucose ([18F]FDG) positron emission tomography/computed tomography (PET/CT) metabolic parameters, clinicopathological characteristics, and sarcopenia in patients with pancreatic ductal adenocarcinoma (PDAC) and evaluates their prognostic roles.
Material and methods
The primary tumor's maximum standard uptake (SUVmax), metabolic tumor volume (MTV), and total lesion glycolysis (TLG) values, as well as clinicopathological factors, were evaluated retrospectively. Computed tomography (CT) was used to assess the skeletal muscle index (SMI). Sarcopenia was defined based on SMI calculated at the third lumbar vertebra (L3). SMI cut-off values for sarcopenia were accepted as 44.77 cm2/m2 for men and 32.50 cm2/m2 for women. The primary endpoint was the overall survival (OS). OS data were analyzed by the Kaplan-Meier method and compared using the log-rank test. To identify predictive factors for sarcopenia, multivariable logistic regression was used following univariable logistic regression. Cox proportional hazards regression analyses were used to find predictors of OS.
Results
Of the 86 patients included in the study, 37 (43%) were diagnosed with sarcopenia. Compared with non-sarcopenic patients, sarcopenia was observed in older patients (P = .028) and patients with lower body mass index (BMI) (P = .001). Age and BMI independently predicted sarcopenia. Univariate analysis identified sarcopenia, advanced stage, and higher primary tumor TLG as significant predictors of overall survival. Multivariate Cox regression analysis revealed that the advanced tumor stage (P = .017) and higher TLG (P = .042) independently predicted OS. The median OS was 9.4 months in non-sarcopenic patients and 5.0 months in sarcopenic patients (P = .021).
Conclusion
In this study cohort, advanced-stage disease and higher primary tumor TLG were identified as independent predictors of OS in patients with PDAC. Additionally, we emphasize the importance of incorporating [18F]FDG PET/CT-derived sarcopenia assessments into the prognostic evaluation and clinical management of PDAC patients. While sarcopenia was associated with shorter OS in univariate analysis, it was not an independent predictor in multivariate analysis.
{"title":"Evaluación del papel de la sarcopenia y de los parámetros de la PET/TC con [18F]FDG en el pronóstico del adenocarcinoma ductal de páncreas","authors":"H. Önner, M.N. Calderon Tobar, L. Perktaş, F. Yilmaz, G. Kara Gedik","doi":"10.1016/j.remn.2024.500046","DOIUrl":"10.1016/j.remn.2024.500046","url":null,"abstract":"<div><div>This study investigates the relationship between <sup>18</sup>F-fluorodeoxyglucose ([<sup>18</sup>F]FDG) positron emission tomography/computed tomography (PET/CT) metabolic parameters, clinicopathological characteristics, and sarcopenia in patients with pancreatic ductal adenocarcinoma (PDAC) and evaluates their prognostic roles.</div></div><div><h3>Material and methods</h3><div>The primary tumor's maximum standard uptake (SUVmax), metabolic tumor volume (MTV), and total lesion glycolysis (TLG) values, as well as clinicopathological factors, were evaluated retrospectively. Computed tomography (CT) was used to assess the skeletal muscle index (SMI). Sarcopenia was defined based on SMI calculated at the third lumbar vertebra (L3). SMI cut-off values for sarcopenia were accepted as 44.77<!--> <!-->cm<sup>2</sup>/m<sup>2</sup> for men and 32.50<!--> <!-->cm<sup>2</sup>/m<sup>2</sup> for women. The primary endpoint was the overall survival (OS). OS data were analyzed by the Kaplan-Meier method and compared using the log-rank test. To identify predictive factors for sarcopenia, multivariable logistic regression was used following univariable logistic regression. Cox proportional hazards regression analyses were used to find predictors of OS.</div></div><div><h3>Results</h3><div>Of the 86 patients included in the study, 37 (43%) were diagnosed with sarcopenia. Compared with non-sarcopenic patients, sarcopenia was observed in older patients (<em>P</em> <!-->=<!--> <!-->.028) and patients with lower body mass index (BMI) (<em>P</em> <!-->=<!--> <!-->.001). Age and BMI independently predicted sarcopenia. Univariate analysis identified sarcopenia, advanced stage, and higher primary tumor TLG as significant predictors of overall survival. Multivariate Cox regression analysis revealed that the advanced tumor stage (<em>P</em> <!-->=<!--> <!-->.017) and higher TLG (<em>P</em> <!-->=<!--> <!-->.042) independently predicted OS. The median OS was 9.4<!--> <!-->months in non-sarcopenic patients and 5.0<!--> <!-->months in sarcopenic patients (<em>P</em> <!-->=<!--> <!-->.021).</div></div><div><h3>Conclusion</h3><div>In this study cohort, advanced-stage disease and higher primary tumor TLG were identified as independent predictors of OS in patients with PDAC. Additionally, we emphasize the importance of incorporating [<sup>18</sup>F]FDG PET/CT-derived sarcopenia assessments into the prognostic evaluation and clinical management of PDAC patients. While sarcopenia was associated with shorter OS in univariate analysis, it was not an independent predictor in multivariate analysis.</div></div>","PeriodicalId":48986,"journal":{"name":"Revista Espanola De Medicina Nuclear E Imagen Molecular","volume":"43 6","pages":"Article 500046"},"PeriodicalIF":1.6,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142658247","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-11-01DOI: 10.1016/j.remn.2024.500054
X. Ruan , Y. Gao
Aim
To investigate the association between positive lesions detected by 99mTc-PSMA SPECT/CT and blood levels of prostate-specific antigen (PSA) and alkaline phosphatase (ALP) in patients with prostate cancer (PCa) and bone metastasis undergoing endocrine therapy.
Methods
A retrospective analysis was performed on 43 patients diagnosed with PCa bone metastasis who underwent endocrine therapy. PSA, ALP, whole body bone imaging and 99mTc-PSMA SPECT/CT imaging were collected from all patients (Among them, 17 cases were re-examined 99mTc-PSMA SPECT/CT imaging). According to the results of the first 99mTc-PSMA SPECT/CT imaging for detecting bone metastasis, all cases were divided into two groups: positive group and negative group. The relationship between 99mTc-PSMA imaging and PSA and ALP was analyzed by ROC curve. Fisher exact probability method was used to examine the changes in imaging radioactivity uptake, PSA, and ALP levels in 17 patients after treatment, and P < 0.05 was statistically significant.
Results
All 43 patients had different degrees of radioactive concentrations on whole-body bone imaging. The first 99mTc-PSMA SPECT/CT imaging showed positive bone metastases in 31 cases and negative bone metastases in 12 cases. ROC curve analysis of PSA and ALP, AUC were 0.778 and 0.770, respectively. When PSA > 1.13 ng/mL, 99mTc-PSMA SPECT/CT imaging diagnostic sensitivity was 93.55%, and specificity was 66.67%. When ALP was >86U/L, the diagnostic sensitivity of 99mTc-PSMA SPECT/CT imaging was 64.52%, and the specificity was 83.33%. In 17 cases, the PSA level decreased in 7 and increased in 10. There were 10 cases of increased ALP and 7 cases of decreased ALP levels. In the second 99mTc-PSMA imaging lesion, there were 9 cases with decreased or no uptake, and 8 cases with increased uptake or number of lesions. The changes in 99mTc-PSMA uptake by Fisher's exact probability method were statistically significant (P < 0.05, P = 0.006, and P = 0.006, respectively), and ALP level was not statistically significant (P = 0.563).
Conclusion
99mTc-PSMA SPECT/CT imaging can detect PCa bone metastases, which are related to PSA levels. When PSA > 1.13 ng/mL, the sensitivity of diagnosis and detection of positive bone metastases is higher, and when ALP is >86U/L, 99mTc-PSMA imaging has higher specificity.
{"title":"Asociación entre las imágenes SPECT/CT con 99mTc-PSMA y los niveles de antígeno prostático específico (PSA) y fosfatasa alcalina (ALP) después de la terapia endocrina en pacientes con cáncer de próstata y metástasis óseas","authors":"X. Ruan , Y. Gao","doi":"10.1016/j.remn.2024.500054","DOIUrl":"10.1016/j.remn.2024.500054","url":null,"abstract":"<div><h3>Aim</h3><div>To investigate the association between positive lesions detected by 99mTc-PSMA SPECT/CT and blood levels of prostate-specific antigen (PSA) and alkaline phosphatase (ALP) in patients with prostate cancer (PCa) and bone metastasis undergoing endocrine therapy.</div></div><div><h3>Methods</h3><div>A retrospective analysis was performed on 43 patients diagnosed with PCa bone metastasis who underwent endocrine therapy. PSA, ALP, whole body bone imaging and 99mTc-PSMA SPECT/CT imaging were collected from all patients (Among them, 17 cases were re-examined 99mTc-PSMA SPECT/CT imaging). According to the results of the first 99mTc-PSMA SPECT/CT imaging for detecting bone metastasis, all cases were divided into two groups: positive group and negative group. The relationship between 99mTc-PSMA imaging and PSA and ALP was analyzed by ROC curve. Fisher exact probability method was used to examine the changes in imaging radioactivity uptake, PSA, and ALP levels in 17 patients after treatment, and <em>P</em> <!--><<!--> <!-->0.05 was statistically significant.</div></div><div><h3>Results</h3><div>All 43 patients had different degrees of radioactive concentrations on whole-body bone imaging. The first 99mTc-PSMA SPECT/CT imaging showed positive bone metastases in 31 cases and negative bone metastases in 12 cases. ROC curve analysis of PSA and ALP, AUC were 0.778 and 0.770, respectively. When PSA<!--> <!-->><!--> <!-->1.13<!--> <!-->ng/mL, 99mTc-PSMA SPECT/CT imaging diagnostic sensitivity was 93.55%, and specificity was 66.67%. When ALP was >86U/L, the diagnostic sensitivity of 99mTc-PSMA SPECT/CT imaging was 64.52%, and the specificity was 83.33%. In 17 cases, the PSA level decreased in 7 and increased in 10. There were 10 cases of increased ALP and 7 cases of decreased ALP levels. In the second 99mTc-PSMA imaging lesion, there were 9 cases with decreased or no uptake, and 8 cases with increased uptake or number of lesions. The changes in 99mTc-PSMA uptake by Fisher's exact probability method were statistically significant (<em>P</em> <!--><<!--> <!-->0.05, <em>P</em> <!-->=<!--> <!-->0.006, and <em>P</em> <!-->=<!--> <!-->0.006, respectively), and ALP level was not statistically significant (<em>P</em> <!-->=<!--> <!-->0.563).</div></div><div><h3>Conclusion</h3><div>99mTc-PSMA SPECT/CT imaging can detect PCa bone metastases, which are related to PSA levels. When PSA<!--> <!-->><!--> <!-->1.13<!--> <!-->ng/mL, the sensitivity of diagnosis and detection of positive bone metastases is higher, and when ALP is >86U/L, 99mTc-PSMA imaging has higher specificity.</div></div>","PeriodicalId":48986,"journal":{"name":"Revista Espanola De Medicina Nuclear E Imagen Molecular","volume":"43 6","pages":"Article 500054"},"PeriodicalIF":1.6,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142658155","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-11-01DOI: 10.1016/j.remn.2024.500058
S. Bondia-Bescós , L.J. Pregil , L. Biassoni
{"title":"Riñón supernumerario fusionado al istmo de un riñón en herradura, con nefroblastoma posterior, identificado en un renograma isotópico","authors":"S. Bondia-Bescós , L.J. Pregil , L. Biassoni","doi":"10.1016/j.remn.2024.500058","DOIUrl":"10.1016/j.remn.2024.500058","url":null,"abstract":"","PeriodicalId":48986,"journal":{"name":"Revista Espanola De Medicina Nuclear E Imagen Molecular","volume":"43 6","pages":"Article 500058"},"PeriodicalIF":1.6,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142658158","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-11-01DOI: 10.1016/j.remn.2024.500052
I. Bolívar Roldán , Ana Moreno Ballesteros , C. Martínez Chinchilla , A. Jiménez-Heffernan , M.C. Calvo Morón
Introduction
To describe the therapeutic efficacy of radiosynoviorthesis with [90Y]Yttrium citrate (90Y), in patients with chronic knee synovitis refractory to systemic treatments and/or infiltrations, correlating the results with the different etiologies and degenerative changes that they showed, in order to optimize the indication of the technique.
Material and methods
Observational retrospective study with 32 patients (22 men and 10 women) and 34 knees, with refractory chronic knee synovitis, who underwent radiosynoviorthesis between January 2013 and December 2022. Its efficacy was described and analyzed by the subjective improvement referred by the patients and its relationship with the existing etiologies and radiological degenerative changes, expressed by the Kellgren-Lawrence (K-L) scale.
Results
A statistically significant subjective improvement was observed in 70.6% of the cases (P< .001). There were 92.3% of cases with absent, doubtful or mild degenerative changes (K-L 0-2) who improved, while only 50% with moderate or severe changes (K-L 3-4) improved, showing statistically significant differences (P = .03). Among patients with chronic inflammatory origin of synovitis (spondyloarthropathies and rheumatoid arthritis), 80% improved, while in those with osteoarthritis (degenerative) origin, only 25% improved with statistically significant differences (P = .006).
Conclusions
Radiosynoviorthesis with 90Y is an effective treatment in patients with knee refractory chronic synovitis, especially in the presence of mil degenerative joint changes and chronic inflammatory origin. We must ensure the appropiate selection of patients according to these criteria.
{"title":"Radiosinoviortesis con [90Y] citrato de ytrio en la sinovitis refractaria de rodilla: experiencia de 2 hospitales de referencia","authors":"I. Bolívar Roldán , Ana Moreno Ballesteros , C. Martínez Chinchilla , A. Jiménez-Heffernan , M.C. Calvo Morón","doi":"10.1016/j.remn.2024.500052","DOIUrl":"10.1016/j.remn.2024.500052","url":null,"abstract":"<div><h3>Introduction</h3><div>To describe the therapeutic efficacy of radiosynoviorthesis with [<sup>90</sup>Y]Yttrium citrate (<sup>90</sup>Y), in patients with chronic knee synovitis refractory to systemic treatments and/or infiltrations, correlating the results with the different etiologies and degenerative changes that they showed, in order to optimize the indication of the technique.</div></div><div><h3>Material and methods</h3><div>Observational retrospective study with 32 patients (22 men and 10 women) and 34 knees, with refractory chronic knee synovitis, who underwent radiosynoviorthesis between January 2013 and December 2022. Its efficacy was described and analyzed by the subjective improvement referred by the patients and its relationship with the existing etiologies and radiological degenerative changes, expressed by the Kellgren-Lawrence (K-L) scale.</div></div><div><h3>Results</h3><div>A statistically significant subjective improvement was observed in 70.6% of the cases <em>(P</em><<!--> <!-->.001). There were 92.3% of cases with absent, doubtful or mild degenerative changes (K-L 0-2) who improved, while only 50% with moderate or severe changes (K-L 3-4) improved, showing statistically significant differences <em>(P</em> <!-->=<!--> <!-->.03). Among patients with chronic inflammatory origin of synovitis (spondyloarthropathies and rheumatoid arthritis), 80% improved, while in those with osteoarthritis (degenerative) origin, only 25% improved with statistically significant differences <em>(P</em> <!-->=<!--> <!-->.006).</div></div><div><h3>Conclusions</h3><div>Radiosynoviorthesis with <sup>90</sup>Y is an effective treatment in patients with knee refractory chronic synovitis, especially in the presence of mil degenerative joint changes and chronic inflammatory origin. We must ensure the appropiate selection of patients according to these criteria.</div></div>","PeriodicalId":48986,"journal":{"name":"Revista Espanola De Medicina Nuclear E Imagen Molecular","volume":"43 6","pages":"Article 500052"},"PeriodicalIF":1.6,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142658153","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-11-01DOI: 10.1016/j.remn.2024.500038
J.R. Garcia, R. Olivero, M. Panelo, L. Mont, L. Pinilla, M.E. Riera, A. Maceira
{"title":"PET/RM cardiovascular con [18F]F-FDG en el diagnóstico de miocardiopatía aguda inflamatoria","authors":"J.R. Garcia, R. Olivero, M. Panelo, L. Mont, L. Pinilla, M.E. Riera, A. Maceira","doi":"10.1016/j.remn.2024.500038","DOIUrl":"10.1016/j.remn.2024.500038","url":null,"abstract":"","PeriodicalId":48986,"journal":{"name":"Revista Espanola De Medicina Nuclear E Imagen Molecular","volume":"43 6","pages":"Article 500038"},"PeriodicalIF":1.6,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141702559","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号